Radiopharmaceuticals Market Research Report by Type, Procedural Volume, Application, Country - North America Forecast to 2027 - Cumulative Impact of COVID-19

The North America Radiopharmaceuticals Market size was estimated at USD 1,240.03 million in 2021 and expected to reach USD 1,297.11 million in 2022, and is projected to grow at a CAGR 5.82% to reach USD 1,741.84 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Radiopharmaceuticals to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine. The Diagnostic Nuclear Medicine is further studied across Pet Radiopharmaceuticals and Spect Radiopharmaceuticals. The Pet Radiopharmaceuticals is further studied across F-18 and Ru-82. The Spect Radiopharmaceuticals is further studied across Ga-67, I-123, Tc-99m, and Tl-201. The Therapeutic Nuclear Medicine is further studied across Alpha Emitters, Beta Emitters, and Brachytherapy Isotopes. The Beta Emitters is further studied across I-131, Lu-177, Re-186, Sm-153, and Y-90. The Brachytherapy Isotopes is further studied across Cs-131, I-125, Ir-192, and Pd-103.

Based on Procedural Volume, the market was studied across Diagnostic Procedures and Therapeutic Procedures. The Diagnostic Procedures is further studied across Pet Radiopharmaceutical Procedure and Spect Radiopharmaceuticals Procedure. The Therapeutic Procedures is further studied across Alpha Emitter Procedure, Beta Emitters Procedure, and Brachytherapy Isotopes Procedure.

Based on Application, the market was studied across Diagnostic Applications and Therapeutic Applications. The Diagnostic Applications is further studied across Pet Applications and Spect Applications. The Pet Applications is further studied across Cardiology Indication, Neurology Indication, and Oncology Indication. The Spect Applications is further studied across Cardiology, Lymphoma, Neurology, and Thyroid. The Therapeutic Applications is further studied across Bone Metastasis, Endocrine Tumors, Lymphoma Therapeutic, and Thyroid Therapeutic.

Based on Country, the market was studied across Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Radiopharmaceuticals market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Radiopharmaceuticals Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the North America Radiopharmaceuticals Market, including Alliance Holdings Medical Limited, Bayer AG, Beijing International Pharmaceutical Technology Co., Ltd., Bracco Group, Cardinal Health, Inc., Clarity Pharmaceuticals, Curium Pharma, Eckert & Ziegler Group, Eczacibasi-Monrol Nuclear Products Co., Fusion Pharmaceuticals Inc., GE Healthcare, Global Medical Solutions, LTD., Institute of Isotopes Co., LTD., IsoTherapeutics Group, LLC, Isotopia Molecular Imaging Ltd., Jubilant Pharma Holdings Inc., Lantheus Medical Imaging, Inc., Mallinckrodt PLC, Navidea Biopharmaceuticals, Inc., Northstar Medical Technologies LLC, Novartis AG, NTP Radioisotopes SOC Ltd., PharmaLogic Holdings LLC, SHINE Medical Technologies, Siemens Healthineers AG, Sotera Health Holdings, LLC, and State Atomic Energy Corporation Rosatom.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the North America Radiopharmaceuticals Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the North America Radiopharmaceuticals Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the North America Radiopharmaceuticals Market?
4. What is the competitive strategic window for opportunities in the North America Radiopharmaceuticals Market?
5. What are the technology trends and regulatory frameworks in the North America Radiopharmaceuticals Market?
6. What is the market share of the leading vendors in the North America Radiopharmaceuticals Market?
7. What modes and strategic moves are considered suitable for entering the North America Radiopharmaceuticals Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Radiopharmaceuticals Market, by Type
6.1. Introduction
6.2. Diagnostic Nuclear Medicine
6.3.1. Pet Radiopharmaceuticals
6.3.2.1. F-18
6.3.2.2. Ru-82
6.3.2. Spect Radiopharmaceuticals
6.3.3.1. Ga-67
6.3.3.2. I-123
6.3.3.3. Tc-99m
6.3.3.4. Tl-201
6.3. Therapeutic Nuclear Medicine
6.4.1. Alpha Emitters
6.4.2. Beta Emitters
6.4.3.1. I-131
6.4.3.2. Lu-177
6.4.3.3. Re-186
6.4.3.4. Sm-153
6.4.3.5. Y-90
6.4.3. Brachytherapy Isotopes
6.4.4.1. Cs-131
6.4.4.2. I-125
6.4.4.3. Ir-192
6.4.4.4. Pd-103

7. Radiopharmaceuticals Market, by Procedural Volume
7.1. Introduction
7.2. Diagnostic Procedures
7.3.1. Pet Radiopharmaceutical Procedure
7.3.2. Spect Radiopharmaceuticals Procedure
7.3. Therapeutic Procedures
7.4.1. Alpha Emitter Procedure
7.4.2. Beta Emitters Procedure
7.4.3. Brachytherapy Isotopes Procedure

8. Radiopharmaceuticals Market, by Application
8.1. Introduction
8.2. Diagnostic Applications
8.3.1. Pet Applications
8.3.2.1. Cardiology Indication
8.3.2.2. Neurology Indication
8.3.2.3. Oncology Indication
8.3.2. Spect Applications
8.3.3.1. Cardiology
8.3.3.2. Lymphoma
8.3.3.3. Neurology
8.3.3.4. Thyroid
8.3. Therapeutic Applications
8.4.1. Bone Metastasis
8.4.2. Endocrine Tumors
8.4.3. Lymphoma Therapeutic
8.4.4. Thyroid Therapeutic

9. Canada Radiopharmaceuticals Market
9.1. Introduction

10. Mexico Radiopharmaceuticals Market
10.1. Introduction

11. United States Radiopharmaceuticals Market
11.1. Introduction

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Alliance Holdings Medical Limited
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Bayer AG
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Beijing International Pharmaceutical Technology Co., Ltd.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bracco Group
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Cardinal Health, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Clarity Pharmaceuticals
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Curium Pharma
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Eckert & Ziegler Group
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Eczacibasi-Monrol Nuclear Products Co.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Fusion Pharmaceuticals Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. GE Healthcare
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Global Medical Solutions, LTD.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Institute of Isotopes Co., LTD.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. IsoTherapeutics Group, LLC
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Isotopia Molecular Imaging Ltd.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Jubilant Pharma Holdings Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Lantheus Medical Imaging, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Mallinckrodt PLC
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Navidea Biopharmaceuticals, Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Northstar Medical Technologies LLC
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Novartis AG
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. NTP Radioisotopes SOC Ltd.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. PharmaLogic Holdings LLC
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. SHINE Medical Technologies
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Siemens Healthineers AG
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Sotera Health Holdings, LLC
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. State Atomic Energy Corporation Rosatom
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing